Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?
Executive Summary
A mega merger combining Pfizer and Wyeth would create a behemoth with combined sales of over $70 billion, build Pfizer's experience base in biotech, give Pfizer the substantial vaccine business it has been searching for and create billions in cost savings opportunities
You may also be interested in...
Pfizer To Buy King Pharma For $3.6 Billion To Boost Pain Franchise
Pfizer's acquisition of King Pharmaceuticals will be the Big Pharma's first "bolt-on" purchase since its mega acquisition of Wyeth in 2009 and fits neatly into a strategy it articulated to a jittery Wall Street for months ("Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?" "The Pink Sheet," Jan. 26, 2009.
Pfizer To Buy King Pharma For $3.6 Billion To Boost Pain Franchise
Pfizer's acquisition of King Pharmaceuticals will be the Big Pharma's first "bolt-on" purchase since its mega acquisition of Wyeth in 2009 and fits neatly into a strategy it articulated to a jittery Wall Street for months ("Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?" "The Pink Sheet," Jan. 26, 2009.
Pfizer To Buy King Pharma For $3.6 billion In Order to Strengthen Pain Franchise
Pfizer will gain access to King's specialized portfolio of medications for acute, severe pain and to Remoxy, which could catapult the Big Pharma into the controversial but promising field of tamper-resistant opioid medications.